FDA Conditionally Approves First Drug to Manage Acute Pancreatitis in Dogs

November 17, 2022 by Dan McCue
FDA Conditionally Approves First Drug to Manage Acute Pancreatitis in Dogs
(Photo by Anna Dudkova via UnSplash)

WASHINGTON — The Food and Drug Administration has conditionally approved Panoquell-CA1 for the management of clinical signs associated with acute onset of pancreatitis in dogs. 

Panoquell-CA1 is an injectable drug intended for use while the dog is hospitalized for treatment of the disease.  

Pancreatitis is a painful inflammatory disease of the pancreas that can be life-threatening and generally requires that dogs be hospitalized for treatment. In most cases, it occurs spontaneously. 

Common factors that increase the chance of developing pancreatitis include when dogs eat something outside of their normal diet (particularly fatty foods), treatment with certain medications, and diseases like diabetes mellitus, the FDA said.

It is more common in certain breeds of dogs and in some dogs may become a recurring or chronic condition. 

“This is the first drug to address a serious and life-threatening disease that previously could only be managed through supportive care, such as intravenous fluids, pain medication, antiemetics, and dietary rest,” said Steven M. Solomon, D.V.M., M.P.H., director of the FDA’s Center for Veterinary Medicine, in a written statement. 

“The conditional approval pathway allows medications like Panoquell-CA1 to reach the marketplace more quickly, and in this case gives dogs suffering from acute onset of pancreatitis earlier access to a drug to manage this disease,”  he said.

Conditional approval means that, when used according to the label, the drug is safe and has a reasonable expectation of effectiveness. 

The initial conditional approval is valid for one year with the potential for four annual renewals. 

During this time, the animal drug sponsor – in this case Ishihara Sangyo Kaisha Ltd. – must demonstrate active progress toward proving substantial evidence of effectiveness for full approval. 

If the sponsor does not meet the requirements for substantial evidence of effectiveness at the conclusion of five years, the product can no longer be marketed.

Fuzapladib sodium, the active ingredient in Panoquell, has been approved since 2018 in Japan to improve clinical signs in the acute phase of pancreatitis in dogs, but not in the United States until Tuesday. 

The FDA reviewed data associated with fuzapladib’s use in Japan as part of its assessment of the application for conditional approval. 

The agency said veterinarians should advise owners about the possible side effects, which include loss of appetite, digestive tract disorders, respiratory tract disorders, liver disease and jaundice, before using the drug. 

It is also encouraging dog owners to work with their veterinarian to report any adverse events or side effects potentially related to the use of any drug, including Panoquell-CA1. 

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue

A+
a-
  • dogs
  • FDA
  • Pancreatitis
  • Panoquell-CA1
  • In The News

    Health

    Voting

    Regulation

    March 26, 2024
    by Dan McCue
    Consumers Warned to Avoid Certain Topical Pain Relief Products 

    WASHINGTON — The Food and Drug Administration warned consumers on Tuesday not to use certain over-the-counter pain relief products marketed... Read More

    WASHINGTON — The Food and Drug Administration warned consumers on Tuesday not to use certain over-the-counter pain relief products marketed for topical use before, during or after certain cosmetic procedures. The warning came after the agency issued warning letters to six companies for marketing these products... Read More

    March 21, 2024
    by Dan McCue
    DOJ, 16 States Sue Apple Over Alleged Smartphone Monopoly

    WASHINGTON — The Justice Department and 16 state attorneys general sued Apple on Thursday accusing the Cupertino, California-based tech giant... Read More

    WASHINGTON — The Justice Department and 16 state attorneys general sued Apple on Thursday accusing the Cupertino, California-based tech giant of operating an illegal monopoly in the smartphone market. According to the lawsuit, which was filed in federal court in New Jersey, Apple has used the... Read More

    Trump Suggests He'd Support a National Ban on Abortions Around 15 Weeks of Pregnancy

    NEW YORK (AP) — Donald Trump suggested Tuesday that he’d support a national ban on abortions around 15 weeks of pregnancy, voicing... Read More

    NEW YORK (AP) — Donald Trump suggested Tuesday that he’d support a national ban on abortions around 15 weeks of pregnancy, voicing for the first time support for a specific limit on the procedure. The Republican former president has taken credit for striking down a federally guaranteed right... Read More

    March 15, 2024
    by Dan McCue
    EPA Sets Tougher Limits on Gas Used to Sterilize Medical Devices

    WASHINGTON — The Environmental Protection Agency on Thursday finalized tougher restrictions on ethylene oxide, a cancer-causing gas commonly used to... Read More

    WASHINGTON — The Environmental Protection Agency on Thursday finalized tougher restrictions on ethylene oxide, a cancer-causing gas commonly used to sterilize medical devices. The new standards specifically target commercial sterilization facilities. The agency called them “the strongest measures in U.S. history to reduce emissions of EtO,”... Read More

    March 15, 2024
    by Dan McCue
    EPA Proposes New Limits on Gas Distribution Facilities

    WASHINGTON — The Environmental Protection Agency on Thursday finalized a rule strengthening toxic air pollution standards at gasoline distribution facilities,... Read More

    WASHINGTON — The Environmental Protection Agency on Thursday finalized a rule strengthening toxic air pollution standards at gasoline distribution facilities, including storage tanks, loading operations and equipment leaks.  The action — from which gas stations are exempt — is expected to reduce emissions of air toxics,... Read More

    March 13, 2024
    by Dan McCue
    FDA Believed Poised to Approve First Med for a Serious Liver Disease

    WASHINGTON — The Food and Drug Administration appears poised to approve the first medicine developed specifically to treat the serious... Read More

    WASHINGTON — The Food and Drug Administration appears poised to approve the first medicine developed specifically to treat the serious liver disease known as MASH later this week.  Metabolic dysfunction-associated steatohepatitis -- formerly known as nonalcoholic steatohepatitis — is often associated with obesity. In patients who... Read More

    News From The Well
    scroll top